Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease by Douglas Galasko, Meifang Xiao, Desheng Xu, Denis Smirnov, David P. Salmon, Nele Dewit, Jeroen Vanbrabant, Dirk Jacobs, Hugo Vanderstichele, Eugeen Vanmechelen, Alzheimer's Disease Neuroimaging Initiative (ADNI), Paul Worley

Get full text

Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy by Giovanni Bellomo, Erik Stoops, Jeroen Vanbrabant, Leentje Demeyer, Cindy Francois, Melanie Vanhooren, Yihua Ma, Carly M. Farris, Luis Concha-Marambio, Federico Paolini Paoletti, Lorenzo Gaetani, Lucilla Parnetti, Davide Chiasserini

Get full text

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 by Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, Bengt Winblad, Erik Stoops, Eugeen Vanmechelen, Norbert Zilka

Get full text

Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217 by Anna L. Wojdała, Jeroen Vanbrabant, Sherif Bayoumy, Daniel Antwi-Berko, Nathalie Le Bastard, Wiesje M. van der Flier, Andreas Jeromin, Charlotte Lambrechts, Maxime Van Loo, Manu Vandijck, Erik Stoops, Inge M. W. Verberk, Charlotte E. Teunissen

Get full text